GlaxoSmithKline News and Research

RSS

FDA's Structured Product Labeling to be discussed

The Center for Business Intelligence (CBI) is pleased to announce the full agenda for their forum on FDA's Structured Product Labeling (SPL R4). The inaugural program will be chaired by Theresa Brunone, Assistant Director, GlaxoSmithKline. The conference will take place in Washington, DC, on December 8-9, 2009.

30 Sep 2009

CEO Cancer Gold Standard accreditation for State Farm

State Farm has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

29 Sep 2009

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.

29 Sep 2009

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

International drug makers are expected to produce three billion doses of the H1N1 (swine flu) vaccine, "enough for just under half the world's population," a WHO official said Thursday, Canwest News Service/Ottawa Citizen reports. "The agency was hoping pharmaceutical companies would be able to make about five billion doses a year, but data collected over the summer led to the revised estimate," the news service writes (Fitzpatrick, 9/24).

25 Sep 2009

Clinton Global Initiative to raise awareness and funding for NTD control and elimination

At the Clinton Global Initiative today, the Inter-American Development Bank joined with the Global Network for Neglected Tropical Diseases to announce their commitment to mobilize $30 million from the public and private sectors to raise awareness and funding for NTD control and elimination in the Americas, supported by technical assistance from the Pan American Health Organization, regional office of the World Health Organization for the Americas.

24 Sep 2009

Top 20 pharma companies seek out new partnering opportunities at BIO-Europe 2009

In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe.

23 Sep 2009

Nine countries pledge H1N1 vaccine donations to developing countries

...

21 Sep 2009

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.

17 Sep 2009

Glaxo conceals risks: Antidepressant drug Paxil causes birth defects

Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline's total revenue last year, has been known to cause birth defects, but the world's second-biggest drugmaker hid its risks to pump up profits, a Philadelphia court has heard.

17 Sep 2009

Unemployed and uninsured to have easy access to free medicines from GSK

GlaxoSmithKline (NYSE: GSK) today announced that it is making free medicines easier to obtain for patients who are unemployed, uninsured or struggling to make ends meet.

17 Sep 2009

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu) vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign, The Wall Street Journal reports. The application for GlaxoSmithKline PLC's vaccine is still being considered (Dooren/Favole, 9/15).

17 Sep 2009

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

16 Sep 2009

Linguistic Systems is MBC's first language translation member

Linguistic Systems, Inc. (LSI), a leading provider of language translation services, today announced that it has joined the Massachusetts Biotechnology Council (MBC) as the first language translation member in the organization.

16 Sep 2009

WHO says 3b people worldwide could receive H1N1 vaccine

Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.

16 Sep 2009

Men and healthcare professionals urged to take proactive approach to prostate cancer

As prostate cancer is the third leading cause of cancer death in European men with more than 300,000 men being diagnosed every year, society needs to commit to changing the way the disease is viewed. Therefore a mini-symposium and lunch meeting are organized on 18 September 2009 in Antwerp on the occasion of the European launch of the Proactive Prostates Initiative, organized as part of Urology Week.

14 Sep 2009

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.

11 Sep 2009

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

PEPFAR on Wednesday donated eight computers to Swaziland's Ministry of Health to aid in the country's ability to track the progress of the nation's HIV/AIDS programs, the Swazi Observer reports. According to the newspaper, the computers will be distributed to regional clinics across the country (Masilela, 9/10).

10 Sep 2009

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

To continue the state life science industry’s record-setting growth rate, the North Carolina Biotechnology Center, with the help of statewide partners, is building an addition to its Research Triangle Park headquarters.

10 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

GlaxoSmithKline News and Research

FDA's Structured Product Labeling to be discussed

CEO Cancer Gold Standard accreditation for State Farm

Ligand and GSK amend agreement to pursue independent research programs

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

WHO lowers expectation of H1N1 vaccine output, appeals for donations to fight pandemic

Clinton Global Initiative to raise awareness and funding for NTD control and elimination

Top 20 pharma companies seek out new partnering opportunities at BIO-Europe 2009

Nine countries pledge H1N1 vaccine donations to developing countries

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

Glaxo conceals risks: Antidepressant drug Paxil causes birth defects

Unemployed and uninsured to have easy access to free medicines from GSK

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

Santaris Pharma establishes its operations in the U.S.

Linguistic Systems is MBC's first language translation member

WHO says 3b people worldwide could receive H1N1 vaccine

Men and healthcare professionals urged to take proactive approach to prostate cancer

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

Business vertical-focused learning solutions for the health care industry launched by TIS

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News